Study ID	Condition	Intervention	Study Design	Sample Size	Age Range	Gender	Duration	Outcome Measures
Srinivasan et al. (2021)	Painful diabetic neuropathy	low dose naltrexone	Randomized, double-blind, active-control, crossover	67	30 - 70	16 M, 20 F	16 weeks	Pain scores
Pontén et al. (2020)	Pain conditioning	naltrexone	Double-blind, placebo-controlled experimental trial	24	18 - 50	14 M, 10 F	2 days	Pain ratings
Bruun et al. (2020)	Fibromyalgia	low dose naltrexone	Single-blinded clinical trial	27	18 - 60	27 F	3 weeks	PGI-I score, Pain scores
Metyas et al. (2018)	Fibromyalgia	low dose naltrexone	Prospective pilot study	25	34 - 62	24 F, 1 M	8 weeks	Pain scores, quality of life
Younger et al. (2013)	Fibromyalgia	low dose naltrexone	Randomized, double-blind, placebo-controlled, counterbalanced, crossover	31	18 - 70	2 M, 29 F	16 weeks	Pain scores
Cree et al. (2010)	Multiple sclerosis	low dose naltrexone	Randomized, double-blind, placebo-controlled	80	18 - 75	30 M, 50 F	6 months	Quality of life
Sharafaddinzadeh et al. (2010)	Multiple sclerosis	low dose naltrexone	Randomized, double-blind, placebo-controlled	40	20 - 50	22 M, 18 F	2 months	Quality of life
Younger et al. (2009)	Fibromyalgia	low dose naltrexone	Pilot study	10	30 - 54	10 F	8 weeks	Pain scores, quality of life
Hamann and Sloan (2007)	Chronic pain	low dose naltrexone	Randomized, double-blind, prospective pilot	20	23 - 65	16 M, 4 F	12 weeks	Pain scores
Kariv et al. (2006)	Irritable bowel syndrome	low dose naltrexone	Pilot study	11	18 - 60	7 M, 4 F	12 weeks	Quality of life
Dieckmann et al. (2022)	Neuropathic corneal pain	low dose naltrexone	Retrospective cohort	29	60 - 65	29 M/F	4 - 12 weeks	Pain scores
Gironi et al. (2008)	Primary progressive multiple sclerosis	low dose naltrexone	Pilot study	40	25 - 50	24 M, 16 F	6 months	Quality of life
Webster et al. (2005)	Low back pain	Oxytrex	Randomized, double-blind, placebo-controlled	40	20 - 60	20 M, 20 F	4 weeks	Pain scores, physical dependence